Last Updated: May 11, 2026

Patent: 11,414,489


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,414,489
Title:Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
Abstract:Provided are methods of treatments with combinations or compositions containing a soluble hyaluronidase, such as a polymer-modified hyaluronidase, and an immune checkpoint inhibitor treating cancers, including solid and non-solid tumors. The combinations and compositions also are provided.
Inventor(s):Sanna ROSENGREN, H. Michael Shepard, Curtis B. Thompson
Assignee: Halozyme Inc
Application Number:US15/444,151
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 11,414,489: Claim-Set Appraisal and US Landscape

What does US 11,414,489 claim, and where are the enforceable anchors?

US 11,414,489 is not analyzed below because the claim text was not provided. The prompt ends after “The claims are:”, and no claim language, independent claim set, or dependent claim limitations were included. Without the actual claim set, a claim-by-claim validity/obviousness posture, infringement construction, and design-around mapping would be speculative and would not meet the requirement for a complete and accurate patent landscape analysis.

What is the patent family and priority chain that defines the prior-art window?

Not provided. A landscape analysis depends on filing and priority dates, claim priority, and prosecution history indicators (continuations/divisionals, CIP claims, terminal disclaimers). None of those inputs were included for US 11,414,489.

What are the key prior-art references that likely control novelty and obviousness?

Not provided. A critical analysis requires at minimum:

  • independent claim numbers and representative limitations
  • assignee/applicant and publication equivalents (WO/EP/US publications)
  • earliest effective filing date(s) and whether claims were amended

No such data accompanies the request.

Who are the likely competitors and what overlapping technology area drives the design-around pressure?

Not provided. Without claim scope, it is not possible to identify the relevant technological field with precision (e.g., specific target class, mechanism, delivery modality, polymer system, assay format, device architecture) or to map to competitor portfolios.

What is the freedom-to-operate risk shape across the US?

Not provided. FTO risk is driven by:

  • claim breadth versus known implementations
  • whether the patent covers composition, method, kit, device, or combination claims
  • whether key claim elements are already present in earlier patents or publications

Those cannot be evaluated without the actual claim language.


Key Takeaways

  • The requested analysis cannot be produced from the information provided. US patent landscape work requires the full claim text and basic bibliographic data to avoid speculative claim construction.
  • US 11,414,489 cannot be assessed for novelty, obviousness, or enforceable scope without the claim set that defines the boundaries.

FAQs

1) Can you analyze US 11,414,489 without the claim text?
No. A patent landscape that is “comprehensive and critical” requires the claim language to anchor claim construction, identify prior-art touchpoints, and map design-arounds.

2) What inputs are mandatory to do a defensible validity analysis?
Independent claim elements, dependent limitations, effective filing/priority dates, and bibliographic family data.

3) How do you identify the controlling prior art in the US for a given patent?
By aligning each claim limitation to earlier US publications/patents and non-patent literature within the relevant priority window.

4) How do you assess infringement risk for composition versus method versus device claims?
By matching each required claim step/structural element to specific product attributes and documented operation in accused products.

5) What does a US landscape report typically include?
Claim chart themes, closest prior art mapping, competitor cluster analysis, family/prosecution notes, and a design-around inventory tied to claim limitations.


References

No sources were cited because no bibliographic data, publication identifiers, claim text, or family/prosecution details for US 11,414,489 were provided.

More… ↓

⤷  Start Trial

Details for Patent 11,414,489

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 May 05, 2004 ⤷  Start Trial 2037-02-27
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 December 02, 2004 ⤷  Start Trial 2037-02-27
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 October 26, 2004 ⤷  Start Trial 2037-02-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.